Amgen (NASDAQ: [[ticker:AMGN]]), the world’s largest biotech company, said today it has won clearance from the FDA to start marketing denosumab (Xgeva) to reduce fractures in cancer patients with solid tumors that have spread to the bones. This is the second major approved use of the drug, which was first cleared in June as a treatment for osteoporosis. Xconomy described Amgen’s strategy for fighting cancer in the bones, and the role of Seattle-based scientist Bill Dougall, back in this story from October 2008.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
